UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/593,503	07/10/2007	John Sondek	5470-413	1695
20792 7590 12/30/2009 MYERS BIGEL SIBLEY & SAJOVEC PO BOX 37428 PALEICH NG 27627			EXAMINER	
			MARTINELL, JAMES	
RALEIGH, NC 27627			ART UNIT	PAPER NUMBER
			1634	
			MAIL DATE	DELIVERY MODE
			12/30/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)		
	10/593,503	SONDEK ET AL.		
Office Action Summary	Examiner	Art Unit		
	James Martinell	1634		
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address		
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be time will apply and will expire SIX (6) MONTHS from cause the application to become ABANDONEI	l. ely filed the mailing date of this communication. D (35 U.S.C. § 133).		
Status				
Responsive to communication(s) filed on <u>21 December</u> 2a) This action is FINAL . 2b) This 3) Since this application is in condition for alloware closed in accordance with the practice under E	action is non-final. nce except for formal matters, pro			
Disposition of Claims				
4) ☐ Claim(s) 2 and 3 is/are pending in the application 4a) Of the above claim(s) is/are withdraw 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) 2 and 3 is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction and/or Application Papers 9) ☐ The specification is objected to by the Examine	vn from consideration. election requirement.	ad to but be Evenings		
10)☑ The drawing(s) filed on 20 September 2006 is/a Applicant may not request that any objection to the o Replacement drawing sheet(s) including the correcti 11)☐ The oath or declaration is objected to by the Ex-	drawing(s) be held in abeyance. See on is required if the drawing(s) is obj	ected to. See 37 CFR 1.121(d).		
Priority under 35 U.S.C. § 119				
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 				
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date 12/21/09.	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:	te		

Art Unit: 1634

The indicated allowability of claims 2 and 3 is withdrawn in view of the newly discovered reference(s) to Rojas et al (Combinatorial Chemistry & High Throughput Screening 6 (4), 409 (June 2003)). Rejections based on the newly cited reference(s) follow.

The citation for Rojas et al (Combinatorial Chemistry & High Throughput Screening 6 (4), 409 (June 2003)), cited by applicants in the Information Disclosure Statement filed December 21, 2009 has been corrected. On December 23, 2009 the web site for the journal, Combinatorial Chemistry & High Throughput Screening, listed the article as appearing on pages 409-418 of the June 2003 issue.

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.

Claims 2 and 3 are rejected under 35 U.S.C. 102(a) as being clearly anticipated by Rojas et al (Combinatorial Chemistry & High Throughput Screening 6 (4), 409 (June 2003)). Rojas et al teaches the discovery of small molecule therapeutics for the inhibition of signal transduction mediated by GTPases (*e.g.*, see the Abstract, page 409, column 1, first full paragraph, paragraph bridging pages 411-412, Figure 3, pages 416-417, and Figure 8) by measuring the difference in rates of fluorescence in a nucleotide exchange assay over time involving Tiam1-catalyed exchange (e.g., compare Figure 4 of the instant application to Figure 8 of Rojas et al). Rojas et al at page 416, column 2, first full paragraph teaches the biochemical characterization of GTPases and their associated guanine nucleotide exchange factors (GEFs). Thus, the methods of Rojas et al anticipate the methods of claims 2 and 3 for screening for compounds that have the ability to inhibit guanine nucleotide exchange factor activity and GTPase activity.

Application/Control Number: 10/593,503 Page 3

Art Unit: 1634

Any inquiry concerning this communication or earlier communications from the examiner should be directed to James Martinell whose telephone number is (571) 272-0719.

The examiner works a flexible schedule and can be reached by phone and voice mail.

Alternatively, a request for a return telephone call may be e-mailed to <u>james.martinell@uspto.gov</u>. Since e-mail communications may not be secure, it is suggested that information in such requests be limited to name, phone number, and the best time to return the call.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dave T. Nguyen, can be reached on (571) 272-0731.

OFFICIAL FAX NUMBER

The fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300. Any Official Communication to the USPTO should be faxed to this number.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

/James Martinell/ Primary Examiner Art Unit 1634